Research Reference
Survodutide
Investigational dual GLP-1/glucagon receptor agonist in Phase 3
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Survodutide is an investigational dual GLP-1 and glucagon receptor agonist in Phase 3 trials for obesity and metabolic-associated steatohepatitis (MASH). It is not FDA approved.
Dosing Reference
Reconstitution
Add 2 mL bacteriostatic water to the 10 mg vial. Resulting concentration: 5 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 0.6 mg | 12 units | 0.12 mL | SubQ, once weeklyPhase 3 starting dose |
| 2.4 mg | 48 units | 0.48 mL | SubQ, once weeklyPhase 3 titration dose |
| 4.8 mg | 96 units | 0.96 mL | SubQ, once weeklyPhase 3 mid dose |
| 9.6 mg | 192 units | 1.92 mL | SubQ, once weeklyPhase 3 target dose |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
Survodutide (BI 456906) is an investigational GLP-1/glucagon dual receptor agonist (Boehringer Ingelheim / Zealand Pharma) in phase 3 trials. It is supplied as a pre-filled pen or lyophilized vial for subcutaneous use. Compounded research-peptide forms are not FDA-approved.
For a compounded 10 mg vial reconstituted with 2 mL, the concentration is 5 mg/mL; a 4.8 mg dose draws to 96 units (0.96 mL) on a U-100 syringe. Store per manufacturer directions; compounded forms are not FDA-approved.
Cycling Protocol
Phase 3 trials (SYNCHRONIZE for obesity, for MASH) titrate survodutide weekly: 0.6 mg → 2.4 mg → 4.8 mg → up to 9.6 mg once weekly over several weeks, then maintained long-term. No fixed cycle end; studied as chronic weekly therapy.
Routes of Administration
Subcutaneous injection (only established route): Once weekly into the abdomen, thigh, or upper arm. Any time of day, independent of meals.
No oral, intranasal, or intravenous route is established. Compounded forms are not FDA-approved.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | Dual agonist + Lifestyle | Survodutide + diet/exercise | Phase 3 obesity/MASH protocol |
Combining multiple GLP-1 agonists is not recommended. Survodutide is investigational and not FDA-approved.
Side Effects & Safety
- Nausea, vomiting, diarrhea, constipation — common, usually transient
- Hypoglycemia — risk, especially combined with insulin/sulfonylureas
- Pancreatitis — rare; discontinue if suspected
- Injection-site reactions — common
- Thyroid C-cell tumors — in rodents; avoid in MTC/MEN2 history
Survodutide is investigational (phase 3) and not FDA-approved. Compounded research-peptide forms are not FDA-approved.
Research Basis
Survodutide (BI 456906) is an investigational GLP-1/glucagon dual receptor agonist (Boehringer Ingelheim / Zealand Pharma), derived from the oxyntomodulin sequence.
Mechanism: Dual GLP-1 and glucagon receptor agonism — GLP-1 effects (appetite suppression, insulin secretion) plus glucagon effects (energy expenditure, hepatic fat oxidation), targeting both weight loss and MASH (metabolic dysfunction-associated steatohepatitis).
Clinical evidence: Phase 2 demonstrated significant weight loss and MASH improvement; phase 3 (SYNCHRONIZE) ongoing for obesity and MASH. Not FDA-approved.
Investigational — not FDA-approved. Compounded research-peptide forms are not FDA-approved.